Repros Therapeutics Inc. (Nasdaq:RPRX) is trading 6% higher today after the company announced ahead of the opening its uterus drug Proellex showed a substantial decrease in pain in patients during its U.S. Phase 2 trial. Repros Therapeutics, a The Woodlands, Texas-based biopharmaceutical company, said patients in the trial experienced a drop in their endometriosis-related pain within one to two months on Proellex.

In today’s trading, Repros Therapeutics is at $9.44, up $0.54 from Thursday’s close. The stock has ranged from $6.99 to $14.38 during the past 52 weeks.

For access to the full article, you must be a registered member - it's FREE.